Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

DRUG2 trials

Sponsors

Daiichi Sankyo Inc., Charite Universitaetsmedizin Berlin KöR

Conditions

Acute myeloid leukemiaRelapsed Acute Lymphoblastic Leukemia (ALL)

Phase 3

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)

RecruitingCTIS2023-507936-20-00

Daiichi Sankyo Inc.Acute myeloid leukemia

Start: 2025-05-05Target: 267Updated: 2025-12-16

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

Not yet recruitingCTIS2023-509392-17-00

Charite Universitaetsmedizin Berlin KöRRelapsed Acute Lymphoblastic Leukemia (ALL)

Target: 765Updated: 2025-12-15

Related Papers

QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in <i>FLT3</i> -ITD–negative acute myeloid leukemia (AML).

Journal of Clinical Oncology2025-05-28

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, <i>FLT3</i>-ITD-Negative Acute Myeloid Leukemia

Blood2024-11-054 citations